Marie-Claude Gagnieu
Overview
Explore the profile of Marie-Claude Gagnieu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parant F, Gagnieu M, Di-Pilla L, Deloire A, Joassard A, Millet A, et al.
Ther Drug Monit
. 2025 Mar;
PMID: 40044655
Background: Posaconazole (PCZ) is recommended for antifungal prophylaxis in neutropenic patients with acute myeloid leukemia (AML). Although the delayed-release (DR) tablet of PCZ has better bioavailability than the oral suspension,...
2.
Lemaitre F, Lagoutte-Renosi J, Gagnieu M, Parant F, Venisse N, Gregoire M, et al.
Br J Clin Pharmacol
. 2023 Aug;
90(1):264-273.
PMID: 37602480
Aims: Dolutegravir (DTG) and rilpivirine (RPV) dual therapy is now recommended as a switch option in virologically suppressed HIV patients. Literature suggests that virological failure with dual therapy could possibly...
3.
Heitzmann J, Thoma Y, Bricca R, Gagnieu M, Leclerc V, Roux S, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35057009
Daptomycin is a candidate for therapeutic drug monitoring (TDM). The objectives of this work were to implement and compare two pharmacometric tools for daptomycin TDM and precision dosing. A nonparametric...
4.
Bienvenu A, Pradat P, Plesa A, Leclerc V, Piriou V, Fellahi J, et al.
PLoS One
. 2021 Nov;
16(11):e0260656.
PMID: 34818379
Therapeutic drug monitoring (TDM) is essential for voriconazole to ensure optimal drug exposure, mainly in critically ill patients for whom voriconazole demonstrated a large variability. The study aimed at describing...
5.
Goutelle S, Conrad A, Pouderoux C, Braun E, Laurent F, Gagnieu M, et al.
Front Med (Lausanne)
. 2021 Apr;
8:583086.
PMID: 33869238
Suppressive parenteral antibiotic therapy with beta-lactams may be necessary in patients with Gram-negative bone and joint infection (BJI). Subcutaneous drug administration can facilitate this therapy in outpatient setting, but there...
6.
Berger M, Lebecque B, Tassin T, Dannus L, Berger J, Soucal M, et al.
Sci Rep
. 2021 Mar;
11(1):6187.
PMID: 33731863
Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in Chronic Phase-Chronic Myeloid Leukaemia (CP-CML) cells constitute a...
7.
Garreau R, Bricca R, Gagnieu M, Roux S, Conrad A, Bourguignon L, et al.
J Antimicrob Chemother
. 2021 Feb;
76(5):1250-1257.
PMID: 33550409
Background: Daptomycin is increasingly used in the treatment of bone and joint infection (BJI), but its pharmacokinetics (PK) and dosage requirements have not been thoroughly investigated in this indication. Daptomycin...
8.
Venisse N, Peytavin G, Bouchet S, Gagnieu M, Garraffo R, Guilhaumou R, et al.
Antiviral Res
. 2020 Jul;
181:104866.
PMID: 32659293
In the context of the COVID-19 pandemic, several drugs have been repurposed as potential candidates for the treatment of COVID-19 infection. While preliminary choices were essentially based on in vitro...
9.
Millet A, Citterio-Quentin A, Gagnieu M, Parant F, Guitton J
Clin Chem Lab Med
. 2020 May;
58(7):1165-1167.
PMID: 32386186
No abstract available.
10.
Parant F, Miailhes P, Brunel F, Gagnieu M
Ther Drug Monit
. 2019 Mar;
41(4):444-451.
PMID: 30817698
Background: There are growing concerns about dolutegravir (DTG)-related neuropsychiatric adverse events and about differences in the characteristics of people living with HIV infection (PLWH) potentially associated with higher risks of...